160641-96-3

Upstream product

• 122-51-0 orthoformic acid triethyl ester 
• 160641-94-1 8-(3-Amino-2,6-dichlorobenzyloxy)-3-bromo-2-methylimidazo[1,2-a]pyridine 
• 160642-06-8 8-(3-acetylamino-2,6-dichlorobenzyloxy)-3-bromo-2-methylimidazo[1,2-a]pyridine 
• 160641-39-4 3-bromo-8-(2,6-dichloro-3-nitrobenzyloxy)-2-methylimidazo[1,2-a]pyridine 
• 160647-05-2 8-(2,6-dichloro-3-nitrobenzyloxy)-2-methylimidazo[1,2-a]pyridine 
• 149976-78-3 2,6-dichloro-1-methanesulfonyloxymethyl-3-nitrobenzene 
• 160647-01-8 2,6-Dichloro-3-nitrobenzyl alcohol 
• 5866-97-7 2,6-dichloro-3-nitrobenzaldehyde 
• 160642-27-3 3-bromo-8-[2,6-dichloro-3-(N-acetyl-N-methylamino)-benzyloxy]-2-methylimidazo[1,2-a]pyridine 

Downstream Products

• 617721-04-7 N-[3-(3-bromo-2-methyl-imidazo[1,2-a]pyridin-8-yloxymethyl)-2,4-dichlorophenyl]-2-[5-(4-cyano-benzoyl)-1-methyl-1H-pyrrol-2-yl]-N-methyl-acetamide trifluoroacetate 
• 160642-21-7 3-bromo-8-[2,6-dichloro-3-[N-methyl-N-(4-nitrophenyloxycarbonyl)amino]benzyloxy]-2-methylimidazo[1,2-a]pyridine 

Relevant academic research and scientific papers

Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators

This invention is directed towards novel alkylamide derivatives as bradykinin receptor antagonists useful for the treatment of bradykinin modulated disorders such as pain, inflammation, asthma and allergy. Furthermore, the present invention is directed to novel alkylamide derivatives as bradykinin receptor agonists useful for the treatment of bradykinin modulated disorders such as hypertension and the like.

NOVEL HETEROARYL ALKYLAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR MODULATORS

This invention is directed towards novel alkylamide derivatives as bradykinin receptor antagonists useful for the treatment of bradykinin modulated disorders such as pain, inflammation, asthma and allergy. Furthermore, the present invention is directed to novel alkylamide derivatives as bradykinin receptor agonists useful for the treatment of bradykinin modulated disorders such as hypertension and the like.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework

A novel class of potent, selective, and orally active non-peptide bradykinin (BK) B2 receptor antagonists were designed and synthesized starting from 8-benzyloxyimidazo[1,2-α]pyridine derivative 2. The unique screening lead (2) was discovered b

IMIDAZO [1,2-A] PYRIDINES AND THEIR PHARMACEUTICAL USE

The invention relates to novel bradykinin antagonists of the formula: STR1 wherein R 1 is halogen,R 2 and R 3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl,R 4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s),Q is O or N--R 11, in which R 11 is hydrogen or acyl, andA is lower alkylene,and pharmaceutically acceptable salts thereof.